Logotype for LENZ Therapeutics Inc

LENZ Therapeutics (LENZ) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for LENZ Therapeutics Inc

Q3 2026 earnings summary

9 Nov, 2026

Executive summary

  • Q3 VIZZ product sales reached $2.6M, up 50% QoQ, with more than 38,000 paid prescriptions and momentum continuing into Q4.

  • The October reorganization redirects resources toward consumer marketing, access and sales growth, targeting a >50% reduction in 2027 operating expenses.

  • CEO Eef Schimmelpennink transitions effective Dec. 1, 2026; CFO Dan Chevallard becomes interim CEO while the board searches for a permanent successor.

Financial highlights

  • Q3 revenue was $3.4M: $2.6M in product sales and $0.8M in license revenue; Q3 2025 revenue was $12.5M, all license revenue.

  • Nine-month 2026 revenue was $10.8M, including $6.0M in product sales and $4.8M in license revenue, versus $17.5M in nine-month 2025, all license revenue.

  • Q3 net loss was $31.0M, or $0.99 per share; nine-month net loss was $104.4M, or $3.33 per share.

  • Cash, cash equivalents and marketable securities totaled $197.3M at Sept. 30, 2026; management expects resources to fund operations for at least 12 months from issuance.

Outlook and guidance

  • 2027 operating expenses target $70M–$75M, excluding stock-based compensation, representing a reduction of >50% from prior estimates.

  • More than 70% of projected 2027 operating spend is allocated to consumer-driven sales and marketing; the planned organization is ~40 FTEs.

  • Reorganization activities are expected to be substantially complete in Q4 2026, with estimated net restructuring charges of $5M.

  • Commercial priorities include broad ECP engagement, consumer demand generation and access through retail, ePharmacy and telehealth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from LENZ Therapeutics